The pending Bartlett case will determine whether Mensing applies to design-defect claims and whether it requires a finding that such claims against generic drug manufacturers are similarly preempted.

FORBES: DOJ/FDA Brief in SCOTUS Generic Drug Preemption Case Hands Plaintiffs New Liability Theories